Literature DB >> 6198077

Presence of prelymphoma cells in the bone marrow of the lymphomagenic virus-treated AKR mouse.

H Takeuchi, A Kato, E F Hays.   

Abstract

Prelymphoma cells (PLC) are defined as cells which give rise to lymphoma cells but are not in themselves autonomous. They are present in the bone marrow of young AKR mice, a strain with a high natural incidence of thymic lymphoma. PLC are identified by transfer of AKR bone marrow into 400-rad-treated F1 recipients, one of the parents being AKR. Normal 1-month-old AKR bone marrow cells result in thymic lymphomas of AKR type in the hybrid recipients after latent periods of 6 to 16 months. In the present study, PLC resulting in lymphoma of AKR type 3 to 4 months after inoculation to irradiated hybrids are described. They are consistently found in the bone marrow of 21- to 28-day-old AKR mice treated at 3 to 5 days of age with a lymphomagenic virus, SL3-3. Long-term culture of these bone marrow cells allows the survival of totipotent hemopoietic stem cells but not of PLC. Thymic stromal remnants prepared from the 21- to 28-day-old virus-treated mice efficiently replicate oncogenic virus; however, they do not contain PLC. This was determined by grafting the remnants to irradiated and nonirradiated hybrid recipients. No AKR type lymphomas developed in the grafted mice. We conclude that the bone marrow of young oncogenic virus-treated AKR mice contains PLC modified by oncogenic virus so that they can produce thymic lymphomas after a shorter latent period than can PLC found in 1-month-old normal AKR mice. The modified PLC are not derived from totipotent marrow stem cells or sequestered in the thymic stroma of virus-treated mice.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198077

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Tissue distribution and timing of appearance of polytropic envelope recombinants during infection with SL3-3 murine leukemia virus or its weakly pathogenic SL3DeltaMyb5 mutant.

Authors:  K Rulli; P A Lobelle-Rich; A Trubetskoy; J Lenz; L S Levy
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus.

Authors:  Karen Rulli; Jack Lenz; Laura S Levy
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Monoclonal proliferation of Friend murine leukemia virus-transformed myeloblastic cells occurs early in the leukemogenic process.

Authors:  B Sola; J M Heard; S Fichelson; M A Martial; F Pozo; D Bordereaux; S Gisselbrecht
Journal:  Mol Cell Biol       Date:  1985-05       Impact factor: 4.272

4.  Thymic dendritic cells are primary targets for the oncogenic virus SL3-3.

Authors:  C H Uittenbogaart; W Law; P J Leenen; G Bristol; W van Ewijk; E F Hays
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

5.  Action site of the gene determining susceptibility to propylnitrosourea-induced thymic lymphomas in F344 rats.

Authors:  H Shisa; M Suzuki
Journal:  Jpn J Cancer Res       Date:  1991-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.